Multiple Sclerosis Research Repository

1. “Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis” by Stephen Hauser et al

-”Unlike RMS, in patients with PPMs there was no association of grouped median 

B-cell levels during the DP with rates of 24 W-CDP during the combined DBP

and OLE”

-”Exposure dependency analysis of 24 W-cCDP was directionally consistent with RMS but did not reach statistical significance”

-”An exposure dependency trend on 24 W-cCDP was also observed across quartiles in patients with PPMS”

-”In RMS, all subgroups with the exceptions of religion the United States and EDSS greater than or equal to 4 showed numerically greater reduction in risk of disability progression in the high-exposure group compared with the low-exposure group”

-”where the treatment effect in high exposure patients with PPMS was markedly reduced”

–greater brain volume reduction was seen in RRMS patients with higher ocrelizaumab exposure; no such association was seen in patients with PPMS

-less grey matter volume reduction aws seen with higher ocrelizumab exposure

-”an increasing body of evidence suggests that progression observed in patients with RMS treated with highly effective DMTs reflects the same or at least very similar pathology with progression observed in SPMS and PPMS.  At present, it is not known to what degree each of these pathologies contributes to progression in different patients and/or different stages of disease”

-”the majority of disability progression was relapse-independent and when relapse-independent CDP (PIRA) was investigated separately here, similar associations were found (data not shown)”: WHY WAS DATA NOT SHOWN? LIKELY BECAUSE OCRELIZUMAB WAS NOT EFFECTIVE AGAINST PIRA!!!